Can integrative biomarker approaches improve prediction of platinum and PARP inhibitor response in ovarian cancer?

Funingana, Ionut-Gabriel, Reinius, Marika A.V., Petrillo, Angelica, Ang, Joo Ern, Brenton, James D.·2021·Seminars in Cancer Biology
DOI 10.1016/j.semcancer.2021.02.008

Cites (217)

Items 201–206 of 206

  1. BRCA1 and RAD51C promoter hypermethylation confer sensitivity to the PARP inhibitor rucaparib in patients with relapsed, platinum-sensitive ovarian carcinoma in ARIEL2 Part 1
    Elizabeth M. Swisher, Maria I. Harrell, Kevin Lin, Robert Louis Coleman, Gottfried E. Konecny, Anna V. Tinker, David M. O’Malley, Iain A. McNeish, S.H. Kaufmann · 2017 · Gynecologic Oncology
  2. Olaparib Maintenance for First-Line Treatment of Ovarian Cancer: Will Solo1 Reset The Standard of Care?
    Rowan E. Miller, Shanthini Mary Crusz, Jonathan Andrew Ledermann · 2019 · Future Oncology
  3. Imatinib in Philadelphia chromosome‐positive chronic phase CML patients: Molecular and cytogenetic response rates and prediction of clinical outcome
    Philipp le Coutre, Karl‐Anton Kreuzer, Il‐Kang Na, Michaela Schwarz, Joachim Lupberger, Matthias Holdhoff, Gökben Baskaynak, Harald Gschaidmeier, Uwe Platzbecker, Gerhard Ehninger et al. · 2003 · American Journal of Hematology
  4. Molecular profiling of mucinous epithelial ovarian carcinomas (mEOC): Opportunities for clinical trials.
    Michael Leonard Friedlander, Kenneth Russell, Sherri Z. Millis, Zoran Gatalica, Andreas Voß · 2015 · Journal of Clinical Oncology
  5. Targeting the PI3K/AKT/mTOR pathway in ovarian cancer
    Fernanda Musa, Robert J. Schneider · 2015 · Translational Cancer Research
  6. Trends in median survival and upfront treatment among women with advanced ovarian cancer in the United States: 2004-2016
    Anne T. Knisely, Caryn M. St. Clair, J.Y. Hou, F. Khoury Collado, Ana Isabel Tergas, Jason Dennis Wright, Alexander Melamed · 2020 · Gynecologic Oncology